Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


A pathway analysis method for genome-wide association studies.

Shahbaba B, Shachaf CM, Yu Z.

Stat Med. 2012 May 10;31(10):988-1000. doi: 10.1002/sim.4477. Epub 2012 Feb 3.


Bayesian gene set analysis for identifying significant biological pathways.

Shahbaba B, Tibshirani R, Shachaf CM, Plevritis SK.

J R Stat Soc Ser C Appl Stat. 2011 Aug 1;60(4):541-557.


A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients.

Gentles AJ, Alizadeh AA, Lee SI, Myklebust JH, Shachaf CM, Shahbaba B, Levy R, Koller D, Plevritis SK.

Blood. 2009 Oct 8;114(15):3158-66. doi: 10.1182/blood-2009-02-202465. Epub 2009 Jul 27.


A novel method for detection of phosphorylation in single cells by surface enhanced Raman scattering (SERS) using composite organic-inorganic nanoparticles (COINs).

Shachaf CM, Elchuri SV, Koh AL, Zhu J, Nguyen LN, Mitchell DJ, Zhang J, Swartz KB, Sun L, Chan S, Sinclair R, Nolan GP.

PLoS One. 2009;4(4):e5206. doi: 10.1371/journal.pone.0005206. Epub 2009 Apr 15.


Electron microscopy localization and characterization of functionalized composite organic-inorganic SERS nanoparticles on leukemia cells.

Koh AL, Shachaf CM, Elchuri S, Nolan GP, Sinclair R.

Ultramicroscopy. 2008 Dec;109(1):111-21. doi: 10.1016/j.ultramic.2008.09.004. Epub 2008 Oct 2.


Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance.

Shachaf CM, Gentles AJ, Elchuri S, Sahoo D, Soen Y, Sharpe O, Perez OD, Chang M, Mitchel D, Robinson WH, Dill D, Nolan GP, Plevritis SK, Felsher DW.

Cancer Res. 2008 Jul 1;68(13):5132-42. doi: 10.1158/0008-5472.CAN-07-6192.


Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.

Shachaf CM, Perez OD, Youssef S, Fan AC, Elchuri S, Goldstein MJ, Shirer AE, Sharpe O, Chen J, Mitchell DJ, Chang M, Nolan GP, Steinman L, Felsher DW.

Blood. 2007 Oct 1;110(7):2674-84. Epub 2007 Jul 10.


Rehabilitation of cancer through oncogene inactivation.

Shachaf CM, Felsher DW.

Trends Mol Med. 2005 Jul;11(7):316-21. Review.


Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy.

Shachaf CM, Felsher DW.

Cancer Res. 2005 Jun 1;65(11):4471-4. Review.


MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer.

Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop JM, Contag CH, Felsher DW.

Nature. 2004 Oct 28;431(7012):1112-7. Epub 2004 Oct 10.


The E47 transcription factor negatively regulates CD5 expression during thymocyte development.

Yang Y, Contag CH, Felsher D, Shachaf CM, Cao Y, Herzenberg LA, Herzenberg LA, Tung JW.

Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3898-902. Epub 2004 Mar 4.


Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer.

Giuriato S, Rabin K, Fan AC, Shachaf CM, Felsher DW.

Semin Cancer Biol. 2004 Feb;14(1):3-11. Review.


Supplemental Content

Loading ...
Support Center